Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.21037/tp.2017.09.10 http://scihub22266oqcxt.onion/10.21037/tp.2017.09.10 C5682380!5682380!29184807     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29184807&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Transl+Pediatr 2017 ; 6 (4): 256-68 Nephropedia Template TP {{tp|p=29184807|t=2017. Zoledronic acid in pediatric metabolic bone disorders |pdf=|usr=}}{{29184807}} gab.com Text Zoledronic acid in pediatric metabolic bone disorders JO: Transl Pediatr http://www.kidney.de/pget.php?&tw=1&pmid=29184807 #FOAvip Zoledronic acid (ZA), a highly potent intravenous bisphosphonate (BP), has been increasingly used in children with primary and secondary osteoporosis due to its convenience of shorter infusion time and less frequent dosing compared to pamidronate. Many studies have also demonstrated beneficial effects of ZA in other conditions such as hypercalcemia of malignancy, fibrous dysplasia (FD), chemotherapy-related osteonecrosis (ON) and metastatic bone disease. This review summarizes pharmacologic properties, mechanism of action, dosing regimen, and therapeutic outcomes of ZA in a variety of metabolic bone disorders in children. Several potential novel uses of ZA are also discussed. Safety concerns and adverse effects are also highlighted. Twit Text FOAVip Zoledronic acid in pediatric metabolic bone disorders ????Transl Pediatr http://www.kidney.de/pget.php?&tw=1&pmid=29184807 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29184807 #FOAvip English Wikipedia <ref>{{Cite pmid|29184807}}</ref> Zoledronic acid in pediatric metabolic bone disorders #MMPMID29184807 Bowden SA; Mahan JD Transl Pediatr 2017[Oct]; 6 (4): 256-68 PMID29184807show ga Zoledronic acid (ZA), a highly potent intravenous bisphosphonate (BP), has been increasingly used in children with primary and secondary osteoporosis due to its convenience of shorter infusion time and less frequent dosing compared to pamidronate. Many studies have also demonstrated beneficial effects of ZA in other conditions such as hypercalcemia of malignancy, fibrous dysplasia (FD), chemotherapy-related osteonecrosis (ON) and metastatic bone disease. This review summarizes pharmacologic properties, mechanism of action, dosing regimen, and therapeutic outcomes of ZA in a variety of metabolic bone disorders in children. Several potential novel uses of ZA are also discussed. Safety concerns and adverse effects are also highlighted. äZoledronic acid in pediatric metabolic bone disorders (epmc).pdf DeepDyve Pubget Overpricing